Icagen shares spike after Pfizer re-ups on pain; S*Bio gets $5M investment; Bad year for IPOs

@FierceBiotech: Novartis wins landmark approval for oral MS drug. Article | Follow @FierceBiotech

 @JohnCFierce: Lundbeck is cutting its R&D staff while shifting to more collaborations on brain diseases. Article | Follow @JohnCFierce

> Icagen will get $5 million from Pfizer after the two companies agreed to extend their pain pact by a year. This is the second extension for Icagen, which remains eligible for $359 million in milestones. Investors seemed to like the sound of that and bid up Icagen's share (ICGND) price by 18 percent this morning. Icagen release | Report

> Singapore-based S*BIO Pte Ltd announced a $5 million investment by Mitsui Ventures. The investment follows the recent completion of patient enrolment for S*BIO's Phase II clinical trials with its orally-active JAK2 inhibitor, SB1518. S*BIO release

> AstraZeneca's experimental cancer drug vandetanib has been simultaneously filed for review in Europe and the U.S. And the FDA says it will give the therapy a priority review. Story

> Ziopharm has won orphan drug status for Zinapar, an experimental drug for aggressive lymphomas. Report

And Finally... The overall state of IPOs in the U.S. remains woeful. Bloomberg found that investors lost money on 61 percent of this year's offerings while 68 percent were forced to cut their prospective price. Story

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.